Načítá se...
Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
ESSENTIALS: Current standard of care (SOC) for pediatric venous thromboembolism (VTE) has limitations. Dabigatran etexilate (DE) versus SOC will be studied in children with VTE in a phase IIb/III trial. A dosing algorithm for DE in children will be assessed guiding dosing. Valuable data on the safet...
Uloženo v:
| Vydáno v: | Res Pract Thromb Haemost |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055566/ https://ncbi.nlm.nih.gov/pubmed/30046738 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12086 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|